Clinical Trials
14 trialsNCT06885697 2026-06-04
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT01851395 2026-05-05
Rapid Autopsy and Procurement of Cancer Tissue
National Institutes of Health Clinical Center (CC)
Terminated
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT06996249 2026-03-03
DuTOC
Dutch Society of Physicians for Pulmonology and Tuberculosis
Recruiting
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT01385722 2025-12-26
Molecular Analysis of Thoracic Malignancies
Stanford University
Enrolling by invitation
NCT07072143 2025-07-18
PARTNER
Azienda Ospedaliera di Padova
Recruiting
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT02688166 2022-10-13
Cardiac MRI Biomarker Testing (GCC 1618)
University of Maryland, Baltimore
Terminated
NCT03023319 2022-06-14
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Augusta University
Phase 1 Completed
NCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01135849 2015-11-17
B-Receptor Signaling in Cardiomyopathy
Stanford University
Completed